Insider sales reported at Revolution Medicines (NASDAQ: RVMD) — specific proceeds disclosed
Rhea-AI Filing Summary
Revolution Medicines: Form 144 notice of proposed resale of Common Stock by an affiliate. The filing lists past sales by Jeff Cislini of $206,483.83 for 2,688 shares on 12/16/2025 and $104,964.80 for 908 shares on 01/21/2026. The record also lists historic restricted stock unit grants of 219, 222, 548, 521, and 543 shares on various grant dates; these grant counts are shown as award history.
Positive
- None.
Negative
- None.
Insights
Form 144 lists proposed reseller activity and prior open-market sales by the reporting person.
The filing records two recent sales by Jeff Cislini: 2,688 shares for $206,483.83 on 12/16/2025 and 908 shares for $104,964.80 on 01/21/2026
Grant history shows multiple restricted stock unit awards across 2022–2025 with discrete share counts; timing and amounts for any proposed resale are the central compliance signals. Cash‑flow treatment for future sales is not stated in the excerpt.
Reported past transactions provide a position and sale history but do not itself indicate planned volume or timing.
The filing itemizes prior RSU grants (dates and share counts) which establish source of shares for potential resale. The two disclosed sales include exact proceeds, making them traceable transactions.
Further filings would be needed to confirm any new proposed resale amounts or distribution methods.